Migraine with brainstem aura
diseaseOn this page
Also known as basilar artery migrainebasilar artery migraine with aurabasilar migrainebasilar-type migraineBickerstaff migrainebrainstem migraineMBAvertebrobasilar migraine
Summary
Migraine with brainstem aura (MONDO:0043219) is a disease and 2 clinical trials. Top therapeutic interventions include topiramate. A subtype of migraine with aura — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | migraine with brainstem aura |
| Mondo ID | MONDO:0043219 |
| ICD-11 | 2022157084 |
| NCIT | C117013 |
| SNOMED CT | 83351003 |
| UMLS | C0270860 |
| MedGen | 82857 |
| GARD | 0005896 |
| Is cancer (heuristic) | no |
Also known as: basilar artery migraine · basilar artery migraine with aura · basilar migraine · basilar-type migraine · Bickerstaff migraine · brainstem migraine · MBA · vertebrobasilar migraine
Disease family
This is a subtype of migraine with aura. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › migraine disorder › migraine with aura › migraine with brainstem aura
Related subtypes (1): familial or sporadic hemiplegic migraine
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00131443 | PHASE2/PHASE3 | COMPLETED | Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine |
| NCT00158002 | PHASE2 | COMPLETED | A Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TOPIRAMATE | 4 | 2 |
Related Atlas pages
- Drugs: Topiramate